BANK VONTOBEL/PUT/ELI LILLY & CO/640/0.1/20.12.24 | Real-time Bid/Ask 07:30:15 2024-07-01 EDT | ||
| 0.57 EUR / 0.59 EUR | -1.69% |
|
| Current month | -58.16% | ||
| 1 month | -59.03% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ELI LILLY AND COMPANY
Latest news about ELI LILLY AND COMPANY
More news
| Date | Price | Change |
|---|---|---|
| 24-07-01 | 0.57 | -3.39% |
| 24-06-28 | 0.59 | -7.81% |
| 24-06-27 | 0.64 | +1.59% |
| 24-06-26 | 0.63 | -4.55% |
| 24-06-25 | 0.66 | -4.35% |
Delayed Quote Börse Stuttgart
Last update July 01, 2024 at 02:44 am
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | PUT |
| Underlying | ELI LILLY AND COMPANY |
| Issuer | 
Vontobel
|
| WKN | VD21NF |
| ISIN | DE000VD21NF3 |
| Date issued | 2024-03-27 |
| Strike | 640 $ |
| Maturity | 2024-12-20 (172 Days) |
| Parity | 10 : 1 |
| Emission price | 2.31 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 3.44 € |
|---|---|
| Lowest since issue | 0.57 € |
| Spread | 0.02 € |
| Spread % | 3.39% |
Company Profile
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
Consensus: Eli Lilly and Company
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
905.4
USD
Average target price
868.9
USD
Spread / Average Target
-4.03%
- Stock Market
- Warrants
- Warrant
